Public Profile

Fresenius Kabi Pharmaceuticals Holding, Llc

Fresenius Kabi Pharmaceuticals Holding, LLC, a prominent player in the global healthcare sector, is headquartered in the United States. Founded in 1996, the company has established itself as a leader in the pharmaceutical and medical device industries, focusing on lifesaving medicines and technologies. With a strong operational presence across North America, Europe, and Asia, Fresenius Kabi is dedicated to providing high-quality intravenous (IV) drugs, infusion therapies, and clinical nutrition products. The company is renowned for its commitment to innovation and quality, offering a diverse portfolio that includes generic injectable medications and specialty pharmaceuticals. Fresenius Kabi's unique approach to patient care and its robust supply chain have positioned it as a trusted partner in hospitals and healthcare facilities worldwide. Notable achievements include a strong market presence and a reputation for excellence in patient safety and product reliability.

DitchCarbon Score

How does Fresenius Kabi Pharmaceuticals Holding, Llc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

27

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Fresenius Kabi Pharmaceuticals Holding, Llc's score of 27 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.

46%

Let us know if this data was useful to you

Fresenius Kabi Pharmaceuticals Holding, Llc's reported carbon emissions

Fresenius Kabi Pharmaceuticals Holding, LLC, headquartered in the US, currently does not provide specific carbon emissions data for recent years, as no emissions figures are available. Consequently, there are no reported Scope 1, 2, or 3 emissions figures to analyse. In the absence of concrete emissions data, it is important to note that the company has not outlined any specific reduction targets or climate commitments. This lack of publicly available information may reflect a broader industry context where many pharmaceutical companies are increasingly focusing on sustainability and carbon reduction initiatives. As the industry evolves, it is anticipated that Fresenius Kabi will align with emerging climate standards and practices, potentially adopting measurable targets in the future to enhance their environmental stewardship.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Fresenius Kabi Pharmaceuticals Holding, Llc's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Fresenius Kabi Pharmaceuticals Holding, Llc is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Fresenius Kabi Pharmaceuticals Holding, Llc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers